Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

• Published in: The lancet oncology 2021-01, Vol.22 (1), p.85-97
• Main Authors: Tan, Antoinette R, Im, Seock-Ah, Mattar, André, Colomer, Ramon, Stroyakovskii, Daniil, Nowecki, Zbigniew, De Laurentiis, Michelino, Pierga, Jean-Yves, Jung, Kyung Hae, Schem, Christian, Hogea, Alexandra, Badovinac Crnjevic, Tanja, Heeson, Sarah, Shivhare, Mahesh, Kirschbrown, Whitney P, Restuccia, Eleonora, Jackisch, Christian
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - analysis; Breast cancer; Breast Neoplasms - chemistry; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer therapies; Chemotherapy; Chemotherapy, Adjuvant; Clinical trials; Diarrhea; Drug therapy; ErbB-2 protein; FDA approval; Female; Heart; Humans; Hyaluronoglucosaminidase - administration & dosage; Immunotherapy; Inflammation; Injection; Injections, Subcutaneous; Intravenous administration; Mammography; Metastasis; Middle Aged; Monoclonal antibodies; Myocardial infarction; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Oncology; Patients; Pharmacokinetics; Receptor, ErbB-2 - analysis; Safety; Surgery; Targeted cancer therapy; Time Factors; Trastuzumab; Trastuzumab - administration & dosage; Trastuzumab - adverse effects; Trastuzumab - pharmacokinetics; Treatment Outcome; Ventricle
• ISSN: 1470-2045; 1474-5488
• DOI: 10.1016/S1470-2045(20)30536-2

A subcutaneous formulation of pertuzumab and trastuzumab with recombinant human hyaluronidase in one ready-to-use, fixed-dose combination vial (pertuzumab, trastuzumab, and hyaluronidase-zzxf) was approved by the US Food and Drug Administration (FDA) on June 29, 2020. We report the primary analysis of the FeDeriCa study, which was designed to assess the pharmacokinetics, efficacy, and safety of the fixed-dose subcutaneous formulation compared to intravenous pertuzumab plus trastuzumab in patients with HER2-positive early breast cancer in the neoadjuvant–adjuvant setting. FeDeriCa, a randomised, open-label, international, multicentre, non-inferiority, phase 3 study, was done across 106 sites in 19 countries. Patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1, HER2-positive, operable, locally advanced, or inflammatory stage II–IIIC breast cancer, and a left ventricular ejection fraction of 55% or more were randomly assigned (1:1), using a voice-based or web-based response system, to receive intravenous pertuzumab (840 mg loading dose, followed by 420 mg maintenance doses) plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg maintenance doses) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks with neoadjuvant chemotherapy. Patients were stratified by hormone receptor status, clinical stage, and chemotherapy regimen. The investigator selected one of the two protocol-approved standard chemotherapy regimens before randomisation. Four cycles of HER2-targeted therapy were administered concurrently with the taxane. After surgery, patients continued the HER2-targeted therapy to receive an additional 14 cycles (total of 18). The primary endpoint was non-inferiority of the cycle 7 pertuzumab serum trough concentration (Ctrough; ie, cycle 8 predose pertuzumab concentration) within the fixed-dose combination for subcutaneous injection versus intravenous pertuzumab plus trastuzumab in the per-protocol pharmacokinetic population (all enrolled patients who adhered to prespecified criteria for pharmacokinetic assessment). Non-inferiority was concluded if the lower bound of the 90% CI of the geometric mean ratio was 0·8 or higher. The safety population included all patients who received at